Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease

作者
Lorenzo Cavagna,Roberto Felice Caporali,Lul Abdì-Alì,Roberto Dore,Federica Meloni,Carlomaurizio Montecucco
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:40 (4): 484-492 被引量:97
标识
DOI:10.3899/jrheum.121026
摘要

OBJECTIVE: To describe the longterm effectiveness and safety of cyclosporine (CYC) in patients with anti-Jo1-positive antisynthetase syndrome with corticosteroid-refractory interstitial lung disease (ILD). METHODS: All patients with anti-Jo1 antisynthetase syndrome referred to our division between June 1991 and February 2010 were retrospectively evaluated for ILD. ILD was assessed using pulmonary function tests (PFT) and/or high-resolution computed tomography (HRCT). Kazerooni score was used to evaluate the HRCT extent of ILD. Prednisone was the first-line treatment in all cases (1 mg/kg/day orally, then tapering). Patients with corticosteroid-refractory or relapsing ILD were then included in this retrospective study. All patients started CYC (3 mg/kg/day) without increasing prednisone dosage. Both PFT and chest HRCT were regularly reassessed during followup. RESULTS: Over the period of study we evaluated 18 patients with antisynthetase syndrome; 17 had ILD (13 women; median age at ILD onset 57 yrs); all patients failed prednisone within 12 months of ILD onset and subsequently started CYC. The median followup on CYC was 96 months [interquartile range (IQR) 57-120 mo]. Upon starting CYC, median forced vital capacity (FVC) was 60% (IQR 56%-70%), median DLCO 60% (IQR 50%-62.75%), and median Kazerooni score 16 (IQR 7-18). After 1 year of CYC, FVC (p = 0.0006), DLCO (p = 0.0010), and total Kazerooni score (p = 0.0002) improved and prednisone was tapered (median reduced from 25 mg/day to 2.5 mg/day; p < 0.0001). The results were substantially maintained including at last available followup. CYC side effects were hypertension (5 patients) and creatinine increase (6 patients). CYC was reduced in 3 cases and withdrawn in 4. Three out of 4 patients who interrupted CYC experienced ILD relapse; 2 patients recommenced low-dose CYC with subsequent ILD control. One patient refused re-treatment and subsequently died. CONCLUSION: CYC is effective and substantially safe in patients with anti-Jo1 antisynthetase syndrome with corticosteroid-refractory ILD. CYC withdrawal may be associated with ILD relapse, and low-dose CYC was effective in ILD control.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
执着的尔容完成签到,获得积分10
3秒前
研友_VZG7GZ的应助被863采纳,获得10
4秒前
Bright完成签到 ,获得积分10
5秒前
秋风的应助被DW采纳,获得10
7秒前
Pursue。完成签到,获得积分10
7秒前
9秒前
TPolymer完成签到,获得积分10
12秒前
脑洞疼的应助被扶竹苏春采纳,获得10
13秒前
化学废材完成签到,获得积分10
14秒前
CodeCraft的应助被hyska采纳,获得10
15秒前
含蓄书桃发布了新的文献求助10
16秒前
16秒前
17秒前
18秒前
健康的魔镜完成签到 ,获得积分10
20秒前
华无剑的应助被DW采纳,获得10
20秒前
21秒前
小乐乐完成签到 ,获得积分10
21秒前
斯文败类的应助被淡淡青枫采纳,获得10
23秒前
24秒前
山海不远发布了新的文献求助10
25秒前
uniphoton完成签到,获得积分10
26秒前
fatal发布了新的文献求助10
28秒前
111发布了新的文献求助10
28秒前
粥粥粥完成签到 ,获得积分10
29秒前
ding的应助被木木采纳,获得10
30秒前
叶上初阳完成签到,获得积分0
30秒前
干咸鱼叔叔完成签到,获得积分10
31秒前
GoGoGo完成签到,获得积分10
32秒前
hitech的应助被fatal采纳,获得10
34秒前
科研通AI6.2的应助被山海不远采纳,获得30
35秒前
含蓄书桃完成签到 ,获得积分10
35秒前
spark发布了新的文献求助10
36秒前
Crazy鑫完成签到,获得积分10
38秒前
39秒前
40秒前
快乐鼠完成签到,获得积分10
42秒前
43秒前
43秒前
WLLLR发布了新的文献求助10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196